Patent ID: 9572877
Date: 2017-02-21
CPC Classifications: A61K,A61P,C12N

Claim:
1. A method for inducing immunity to an antigen in a subject comprising administering to the subject a pharmaceutically effective amount of a vaccine composition comprising: (a) a pathogen-derived antigen selected from a group consisting of influenza virus antigen, Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, Varicella-zoster virus antigen which is live attenuated Varicella-zoster virus, inactivated attenuated Varicella-zoster virus, gpI or gpII, HAV (Hepatitis A virus) antigen, HCV (Hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, HSV (Herpes simplex virus) antigen, Hib ( Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheria antigen, Bordetella pertussis antigen and Clostridium tetani antigen; (b) a deacylated non-toxic LOS (Lipooligosaccharide) having a molecular weight in a range of 2,000-4,000Da, obtained by deacylation of lipid A of lipopolysaccharide isolated from Escherichia coli ; and (c) a pharmaceutically acceptable carrier, with the proviso that the vaccine composition does not include an oligodeoxynucleotide (ODN) as an adjuvant.